Preventing saphenous vein graft failure: Does gene therapy have a role?

Annals of Thoracic Surgery

Volumn 76, Issue 3, 2003, Pages 959-966

  Akowuah, Enoch F ^a   Sheridan, Paul J ^b   Cooper, Graham J ^b   Newman, Christopher ^b  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTOKINE; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; LIPOSOME; LUCIFERASE; NAKED DNA; NITRIC OXIDE SYNTHASE; POLYMER; PROTEIN KINASE; THYMIDINE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR E2F; VIRUS VECTOR;

ANGIOGRAPHY; ARTERY GRAFT; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG SAFETY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GRAFT FAILURE; HUMAN; HUMAN GENOME; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; REOPERATION; REPORTER GENE; REVIEW; SAPHENOUS VEIN GRAFT; SMOKING CESSATION; SMOOTH MUSCLE FIBER; SURGICAL TECHNIQUE; VEIN BYPASS; VIRAL GENE DELIVERY SYSTEM;

GENE THERAPY; GRAFT REJECTION; HUMANS; SAPHENOUS VEIN;

EID: 0043282666     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)00505-8     Document Type: Review

References (68)

1. Campeau L, et al. The relationship of risk factors to the development of atherosclerosis in saphenous vein bypass grafts, and the progression of disease in the native circulation; a study 10 years after aortocoronary bypass surgery. N Engl J Med 1984;311:1329-32.
2. Bourassa M. Fate of venous grafts: the past, the present and the future. J Am Coll Cardiol 1991;5:1081-3.
3. Fitzgibbon G, Kafka HP, Leach AJ, Keon WJ, Hooper D, Burton J. Coronary bypass graft fate and patient outcom: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616-26.
4. Cameron A, Davis K, Rogers W. Recurrence of angina after coronary artery bypass surgery: predictors and prognosis (CASS Registry). J Am Coll Cardiol 1995;4:895-9.
5. Weintrab W, et al. Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous vein grafts. Am J Cardiol 1994;73:103-12.
6. Angelini GD, Passani SL, Brekenridge IM, Newby AC. Nature and pressure dependence of damage induced by distension of human saphenous vein coronary artery bypass grafts. Cardiovasc Res 1987;21:902-7.
7. Verrier E, Boyle E. Endothelial cell injury in cardiovascular surgery. Ann Thorac Surg 1996;62:915-22.
8. Angelini GD, Bryan A, Lewis MJ. Preparation of human saphenous vein for coronary artery bypass grafting impairs its capacity to release endothelial derived relaxant factor [Abstract]. Br Heart J 1988;59:613.
9. Angelini GD, Psaila JV, Williams JM, Henderson AH, Newby AC. Preparation of human saphenous vein for coronary artery bypass grafting impairs its capacity to produce prostacyclin. Cardiovasc Res 1987;21:28-33.
10. Groves HM, Kinclough-Rathbone RL, Mustard JF. Development of non-thrombogenicity of injured rabbit aortas despite inhibition of platelet adherence. Arteriosclerosis 1986;6:189-95.
11. Rao GN, Berk GC. Active oxygen species stimulate vascular smooth muscle cell growth, and proto-oncogene expression. Circ Res 1992;70:593-9.
12. Angelini GD, Newby AC. The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J 1989;10:273-80.
13. Angelini G, et al. Time-course of medial, and intimal thickning in pig venous arterial grafts: relationship to endithelial injury and cholesterol accumulation. J Thorac Cardiovasc Surg 1992;03:1093-103.
14. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of artherosclerosis. Nature Med 2002;8:403-9.
15. Yang Z, Oemar BS, Carrel T, Kipfer B, Julmy F, Luscher TF. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation 1998;97:181-7.
16. Shafi S, Palinski W, Born GV. Comparison of uptake and degradation of low density lipoproteins by arteries and veins of rabbits. Atherosclerosis 1987;66:131-8.
17. Lytle B, et al. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1989;89:248-58.
18. Loop FD, et al. Influence of the internal-mammary-artery graft on 10-year survival, and other cardiac events. N Engl J Med 1986;314:1-6.
19. Cameron A, Green G, Schaff HV. Coronary bypass surgery with internal thoracic artery grafts: effect on survival after a 15-year period. N Engl J Med 1996;334:216-20.
20. Dewar LR, JW, Janusz MT, Adeli-Sardo M, Germann E, McNab JS. Unilateral versus bilateral internal mammary revascularization: survival and event-free performance. Circulation 1995;92(Suppl 9):II8-13.
21. Berreklouw E, SJ, Ercan H, et al. Does it make sense to use two internal thoracic arteries? Ann Thorac Surg 1995;59:1456-63.
22. Lytle B, Loop F. Superiority of bilateral internal thoracic artery grafting: it's been a long time comin'. Circulation 2001;104:2152-4.
23. Endo M, et al. Benefit of bilateral over single internal mammary artery grafts for multiple coronary artery bypass grafting. Circulation 2001;104:2164-70.
24. Lytle BW, Blackstone EH, Loop FD. Two internal thoracic arteries are better than one. J Thoracic Cardiovasc Surg 1999;117:855-72.
25. Cohen G, TM, Sever J, Liaghati N, Fremes SE. The radial artery versus the saphenous vein graft in contemporary CABG: a case-matched study. Ann Thorac Surg 2001;71:180-6.
26. Tatoulis J, RA, Buxton BF, et al. The radial artery in coronary surgery: a 5-year experience: clinical and angiographic results. Ann Thorac Surg 2002;73:143-8.
27. Sakaguchi G, TE, Ohnaka M, Tambara K, Nishimura K, Komeda M. Composite arterial Y graft has less coronary flow reverse than independent grafts. Ann Thorac Surg 2002;74:493-6.
28. The Society of Cardiothoracic Surgeons of Great Britain and Ireland. The United Kingdom Cardiac Surgical register; The National adult cardiac Surgical Database Report 1999-2000.
29. FitzGibbon GM, Leach AJ, Kafka HP. Atherosclerosis of coronary artery bypass grafts and smoking. Can Med Assoc J 1987;136:45-7.
30. Voors AA, van Brussel BL, Plokker HW, et al. Smoking and cardiac events after venous coronary bypass surgery: a 15-year follow-up study. Circulation 1996;93:42-7.
31. Goldman S, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988;77:1324-32.
32. Goldman S, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1989;80:1190-7.
33. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1359-60.
34. Porter KE, Turner NA. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans 2002;2:120-6.
35. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med 1997;336:153-62.
36. Nabel EG, PG, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989;244:1342-4.
37. Dichek DA, et al. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 1989;80:1347-53.
38. Baek S, March K. Gene therapy for restenosis: getting nearer the heart of the matter. Circ Res 1998;82:295-305.
39. Leclerc G, et al. Percutaneous arterial gene transfer in a rabbit model: efficiencey in normal and balloon dilated artheroscleritic arteries. J Clin Invest 1992;90:936-44.
40. Guzman R, et al. Efficient and selective adenovirus mediated gene transfer into vascular neointima. Circulation 1993;88:2838-48.
41. Schneider M, French B. The advent of adenovirus: gene therapy for cardiovascular disease. Circulation 1993;88:1937-42.
42. Schulick AH, et al. In vivo gene transfer into injured carotid arteries: optimization and evaluation of acute toxicity. Circulation 1995;91:2407-14.
43. Newman KD, et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995;96:2955-65.
44. Schulick AH, et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries: potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 1997;99:209-19.
45. Lafont A, et al. Vasomotor dysfunction early after exposure of normal rabbit arteries to an adenoviral vector. Hum Gene Ther 1997;8:1033-40.
46. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999;401:517-8.
47. Lawrie A, et al. Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro. Circulation 1999;99:2617-20.
48. Lawrie A. Effect of ultrasound on vascular gene transfer in cardiovascular research group. Sheffield: University of Sheffield, 2001:230.
49. Akowuah E, AM, Gray C, et al. Endoluminal ultrasound enhances non-viral gene delivery from plasmid coated stents. Am J Cardiol 2002;90(Suppl 6A):119.
50. Taniyama Y, TK, Hiroaka K, et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002;105:1233-9.
51. Taniyama Y, et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther 2002;9:372-80.
52. Mann M, et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clinical Invest 1997;99:1295-301.
53. Simari R, et al. Regulation of cellular proliferation and intimal formation following balloon injury inartherosclerotic rabbit arteries. J Clin Invest 1996;98:225-35.
54. Holt CM, et al. Comparison of response to injury in organ culture of human saphenous vein and internal mammary artery. Ann Thorac Surg 1993;55:1522-8.
55. Cable DG, et al. Recombinant endothelial nitric oxide synthase-transduced human saphenous veins: gene therapy to augment nitric oxide production in bypass conduits. Circulation 1997;96(Suppl 9):II173-8.
56. Cable DG, CJ, Caplice N, et al. The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation 1999;100(suppl II):II392-6.
57. Shi Y, et al. Adventitail remodelling after coronary artery injury. Circulation 1996;93:340-8.
58. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996;78:38-43.
59. George SJ, et al. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998;9:867-77.
60. George SJ, et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000;101:296-304.
61. Mann MJ, et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995;92:4502-6.
62. Shitani T, SY, Takahasi T, et al. Intraoperative transfection of vein grafts with the NFkB decoy in a canine aortocoronary bypass model: a strategy to attenuate intimal hyperplasia. Ann Thorac Surg 2002;74:1123-37.
63. Mann M, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy, the PREVENT single-centre randomised, controlled trial. Lancet 1999;354:1493-8.
64. Ferber D. Gene therapy: safer and virus free. Science 2001;294:5547.
65. Mannion JD, Ormont ML, Shi Y, et al. Saphenous vein graft protection: effects of c-myc antisense. J Thorac Cardiovasc Surg 1998;115:152-61.
66. Mannion JD, Ormont ML, Magno MG, O'Brein JE, Shi Y, Zalewski A. Sustained reduction of neointima with c-myc antisense oliginucleotides in saphenous vein grafts. Ann Thorac Surg 1998;66:1948-52.
67. George SJ. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr Opin Lipidol 1998;9:413-23.
68. George SJ, Boker AH, Angelini GD, et al. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 1998;5:1552-60.